

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
i iovisional consultees	
Company Incyte Biosciences UK (Retifanlimab) Patient/carer groups Anal Cancer Foundation Black Health Agency for Equality Bladder and Bowel UK Bowel Cancer UK Bottom Line Cancer 52 Cancer Black Care Colostomy UK Crohn's and Colitis UK IA: Ileostomy and Internal Pouch Group Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie OG Support Pelican Cancer Foundation South Asian Health Foundation	 Submit or appeal) General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government Other relevant companies Hospira UK (docetaxel)
Specialised Healthcare AllianceTenovus Cancer Care	Medac Pharma (folinic acid)Seacross Pharmaceuticals (docetaxel)
 Healthcare professional groups Association of Cancer Physicians Association of Coloproctology of Great Britain and Ireland Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland British Geriatrics Society British Institute of Radiology 	 Possible comparator companies Almirall (fluorouracil) Amarox (capecitabine, cisplatin) Bristol Myers Squibb Pharmaceuticals (paclitaxel) Dr. Reddy's Laboratories (UK) (capecitabine)

Provisional stakeholder list for the evaluation of retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482



Provisional Consultees Provisional Commentators (no right to submit or appeal) **British Oncology Pharmacy** Genus Pharmaceuticals (paclitaxel) Association Glenmark Pharmaceuticals Europe British Psychosocial Oncology Society (capecitabine) British Sarcoma Group Hospira UK (carboplatin, cisplatin, British Society of Gastroenterology docetaxel, fluorouracil, paclitaxel) Cancer Research UK Medac Pharma (fluorouracil, folinic acid, Primary Care Society for mitomycin) Gastroenterology Royal College of General Practitioners Sandoz (cisplatin) Royal College of Nursing Seacross Pharmaceuticals (docetaxel, Royal College of Pathologists paclitaxel) Royal College of Physicians Teva UK (paclitaxel) Royal College of Radiologists Vygoris (mitomycin) Royal Pharmaceutical Society Royal Society of Medicine Relevant research groups Society and College of Radiographers **Bowel Research UK UK Clinical Pharmacy Association** Cochrane Colorectal Group **UK Oncology Nursing Society** Foundation for Liver Research Genomics England Others Institute of Cancer Research Department of Health and Social Care MRC Clinical Trials Unit **NHS** England National Institute for Health Research Associated Public Health groups **Public Health Wales UK Health Security Agency**

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

Provisional stakeholder list for the evaluation of retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482

Issue date: October 2025



organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.